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Taurine regulates insulin release from pancreatic
beta cell lines
William J L’Amoreaux1,2,3,4*, Christina Cuttitta1†, Allison Santora1†, Jonathan F Blaize1,2, Janto Tachjadi1,2,
Abdeslem El Idrissi1,2,4
From 17th International Meeting of Taurine
Fort Lauderdale, FL, USA. 14-19 December 2009

Abstract
Background: Pancreatic b-cells release insulin via an electrogenic response triggered by an increase in plasma
glucose concentrations. The critical plasma glucose concentration has been determined to be ~3 mM, at which
time both insulin and GABA are released from pancreatic b-cells. Taurine, a b-sulfonic acid, may be transported into
cells to balance osmotic pressure. The taurine transporter (TauT) has been described in pancreatic tissue, but the
function of taurine in insulin release has not been established. Uptake of taurine by pancreatic b-cells may alter
membrane potential and have an effect on ion currents. If taurine uptake does alter b-cell current, it might have
an effect on exocytosis of cytoplasmic vesicle. We wished to test the effect of taurine on regulating release of
insulin from the pancreatic b-cell.
Methods: Pancreatic b-cell lines Hit-TI5 (Syrian hamster) and Rin-m (rat insulinoma) were used in these studies. Cells
were grown to an 80% confluence on uncoated cover glass in RPMI media containing 10% fetal horse serum. The
cells were then adapted to a serum-free, glucose free environment for 24 hours. At that time, the cells were treated
with either 1 mM glucose, 1 mM taurine, 1 mM glucose + 1 mM taurine, 3 mM glucose, or 3 mM glucose + 1 mM
taurine. The cells were examined by confocal microscopy for cytoplasmic levels of insulin.
Results: In both cell lines, 1 mM glucose had no effect on insulin levels and served as a control. Cells starved of
glucose had a significant reduction (p<0.001) in the level of insulin, but this level was significantly higher than all
other treatments. As expected, the 3 mM glucose treatment resulted in a statistically lower (p<0.001) insulin level
than control cells. Interestingly, 1 mM taurine also resulted in a statistically lower level of insulin (p<0.001)
compared to controls when either no glucose or 1 mM glucose was present. Cells treated with 1 mM taurine plus
3 mM glucose showed a level of insulin similar to that of 3 mM glucose alone.
Conclusions: Taurine administration can alter the electrogenic response in b-cell lines, leading to a change in
calcium homeostasis and a subsequent decrease in intracellular insulin levels. The consequence of these actions
could represent a method of increasing plasma insulin levels leading to a decrease in plasma glucose levels.

Background
The endocrine pancreas is regulated by neurotransmitters, including the use of glutamate and GABA to regulate insulin and glucagon release as well as somatostatin
to regulate both a- and b-cell activities. For insulin
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release, a rise in extracellular glucose to ~3 mM initiates
co-release of insulin and GABA [1]. The elevated glucose likely stimulates the release of insulin and GABA
from the synapse-like microvesicles (SLMV) through
changes in ion currents in b-cells [2,3]. While the insulin is free to move to the circulatory system through the
interstitial fluid, GABA binds to GABAA receptors on
acells, causing the hyperpolarization of the a-cells, and
inhibiting release of glucagon. Glutamate released from
a-cells binds to GluR4 receptors on δ-cells, increasing
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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the release of SST [4]. SST binds either to the SSTR2
receptor on the a-cell or the SSTR1 and/or SSTR5
receptor on the b-cell. SSTR2 activation maintains the
GABA-initiated inhibition of glucagon from a-cells,
while the SSTR1/5 receptors are responsible for inhibiting insulin release [5].
Taurine (2-aminoethanesulfonic acid) is a sulfur-containing amino acid and is developmentally high in neonates, especially in the brain, and the levels decline to
reach stable adult concentrations that are second to
those of glutamate in the brain. In the adult, taurine is
responsible for maintaining intracellular osmotic balance
in a variety of cells examined [6-8]. In the non-obese
diabetic mouse model, taurine alters islet development
[9]. Previous work done in our laboratory demonstrate
that taurine administration during early development in
the mouse causes an increase in the number and size of
pancreatic islets, without affecting the exocrine portion
of the organ [10]. Further, resting plasma glucose levels
in these mice were significantly lower than in agematched controls (manuscript in preparation). When we
examined the relative immunoreactivity of insulin, glucagon, and somatostatin in the pancreas of these mice,
we found a significant increase in the levels of all three
islet markers.
To determine the level at which taurine may interact
with the pancreatic b-cells, we set out to test our
hypothesis that taurine influences insulin release
through its electrogenic transport into the cell. We used
immunohistochemistry to address relative intracellular
levels of insulin in Hit-T15 (pancreatic b-cell line) and
Rin-m (insulinoma) cells.

3 mM glucose, 1 mM glucose + 1 mM taurine, or 3
mM glucose + 1 mM taurine. Immunohistochemistry.
Following treatment with the supplemented media, cultures were rinsed in 37 o C phosphate-buffered saline
(PBS) then fixed in 4% paraformaldehyde in PBS. The
fixed cells were rinsed in PBS and nonspecific binding
blocked with 4% nonfat dry milk, 4% normal goat serum
and 0.05% Triton X-100 in PBS. Following blocking, the
cultures were incubated with a mouse anti-insulin antibody (Zymed) diluted 1:400 in antibody dilution buffer
(1% nonfat dry milk, 2% normal goat serum in PBS).
Antibodies were incubated for overnight at 4 o C with
constant agitation. Excess unbound antibody was
removed by rinsing in antibody dilution buffer. Following these rinses, the primary antibodies were detected
using a goat anti-mouse IgG conjugated with Alexa
Fluor 488 (Invitrogen Molecular Probes, Carlsbad CA)
or goat anti-mouse IgG conjugated with Alexa Fluor
633 (Invitrogen Molecular Probes, Carlsbad CA). The
secondary antibodies were diluted 1: 500 in antibody
dilution buffer and cultures incubated for 1 hour at
room temperature with constant agitation. Excess
unbound secondary antibody was removed by rinses in
PBS. The cover glass were placed on a drop of antifade
(Slow Fade Gold Plus with DAPI; Invitrogen, Carlsbad
CA) and sealed to the microscope slide with nail polish
and imaged by confocal microscopy (Leica SP2 AOBS).
Laser lines utilized were 405 nm for DAPI, 488 nm for
Alexa Fluor, and 633 nm for Cy5. Images were collected
using a sequential scan mode to prevent overlap of the
DAPI and Alexa Fluor signals. Post-acquisition analyses
of relative fluorescence activities were performed by
both the Leica software and Imaris X64 (Bitplane Scientific Software, Saint Paul MN).
Statistical Analyses. Data from each set of experiments
were analyzed by InStat Software (GraphPad Software,
La Jolla CA). A one-way ANOVA indicated a significant
difference amongst the means (p< 0.001) The Bonferroni multiple comparisons test was then used to
compare treatments.

Methods
Cell Culture. Pancreatic b-cell lines Hit-T15 from Syrian
hamster (CRL-1777; ATCC, Manassas VA) or Rin-m
(CRL-2057; ATCC) were used for these experiments.
Our rationale to use two cell lines arises from the biochemical differences between the two lines. The Hit
cells exhibit characteristics of normal b-cells in that
insulin production decreases with age and they express
receptors for glucagon and somatostatin. The Rin-m
cells are pancreatic islet tumor cells and overproduce
insulin. All cells were from early passages to prevent
passage-dependent decreases of insulin synthesis by the
Hit cells. Cells were grown in RPMI medium containing
2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10%
horse serum, 2.5% fetal bovine serum, 50 U penicillin
and 50 μg streptomycin (Invitrogen, Carlsbad CA) at
37oC, 5% CO2. For treatment, cells were plated in complete medium on sterile cover glass at 5,000 cells/cm2
until ~80% confluent. The media were removed and
replaced with glucose-free RPMI medium that was supplemented with either 1 mM glucose, 1 mM taurine,

Results
Pancreatic b-cells respond to glucose when interstitial
fluid levels reach ~3 mM. When we incubate either
b-cell line in 1 mM glucose, we find that there are
substantial amounts of insulin present in the cytoplasm
(Figs. 1b, 2b, 3). Because of the physiological relatedness of this condition, we use the 1 mM glucose as a
control for these experiments. When the cells are glucose-starved, there is a significant reduction in the
amount of cytoplasmic insulin (Figs. 1a, 2a, 3), likely
due to ATP-dependent changes in the KATP-channels.
When the cells are treated with 3 mM glucose to
approximate in vivo conditions, we see a substantial

L’Amoreaux et al. Journal of Biomedical Science 2010, 17(Suppl 1):S11
http://www.jbiomedsci.com/content/17/S1/S11

Page 3 of 8

Figure 1 Insulin immunoreactivity in Hit pancreatic b-cell line. To test the efficacy of taurine in releasing insulin from the pancreatic b-cell
line cultures were treated with no taurine (A-C) or 1 mM taurine (D-F) in increasing glucose concentrations. Cultures received either 0 mM
glucose (A, D), the subthreshold concentration 1 mM glucose (B, E), or a concentration shown to initiate glucose release (3 mM; C, F). For
controls, we chose the 1 mM glucose without taurine treatment, a condition that does not promote insulin release from b-cells. Cultures were
immunostained for insulin (red). Blue structures are nuclei counterstained with DAPI. Insulin levels were significantly decreased in all cultures
compared to the control cultures (see Figure 3).

decrease (p<0.001) in insulin immunoreactivity in the
cells (Figs. 1c, 2c, 3).
Interestingly, when cells are treated with 1 mM taurine, there is also a significant decrease (p<0.001) in cytoplasmic insulin levels in the cells (Figs., 1d, 2d, 3). In the
Hit cells, this decrease is similar to that seen in the glucose-deprived condition (0G0T), with a p value > 0.05
comparing the two treatments. Comparing all other
groups, each observed value was statistically different
than all others with the exception of the cells treated
with 3 mM glucose and 3 mM glucose plus taurine.
This suggests that the 3 mM glucose is the overriding
stimulus for insulin release.
For the insulinoma cells, again all treatments resulted
in a significant decrease in insulin immunoreactivity

(p<0.001) compared to controls. As with the Hit cells,
insulin immunoreactivity in the presence of 3 mM glucose, while significantly lower than controls, were not
significantly different from each other (p>0.05). Of
interest, we found that there were no significant differences between Rin cells treated with 3 mM glucose and
those treated with 1 mM taurine in the absence of glucose (p>0.05; Fig. 3). Likewise, when taurine is in the
presence of glucose, the concentration of glucose does
not affect the amount of insulin released as both treatments resulted in no significantly different values for
insulin levels (p>0.05). This would seem to indicate that
in the insulinoma cell line, either 3 mM glucose or
1 mM taurine could elicit insulin release as effectively
as the other.
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Figure 2 Insulin immunoreactivity in Rin pancreatic insulinoma cell line. To test the efficacy of taurine in releasing insulin from the
insulinoma cell line cultures were treated with no taurine (A-C) or 1 mM taurine (D-F) in increasing glucose concentrations. Cultures received
either 0 mM glucose (A, D), the subthreshold concentration 1 mM glucose (B, E), or a concentration shown to initiate glucose release (3 mM;
C, F). Cultures were immunostained for insulin (green). Blue structures are nuclei counterstained with DAPI.

The Hit cells treated with 1 mM taurine contained
more insulin than those treated with 3 mM glucose
(Fig. 3), suggesting that different mechanisms exist in
normal b-cells than insulinoma cells with regard to
sensitivity to taurine-regulated insulin release. When
cells were treated with 1 mM glucose (subthreshold)
plus 1 mM taurine, both cell lines responded with a
significant reduction (p<0.001) in the amount insulin
retained compared to controls (Figs. 1e, 2e, 3). In both
cell lines, this treatment resulted in significantly higher
insulin levels compared to cells treated with 3 mM
glucose (p<0.001 for Hit cells; p<0.01 for Rin cells).
For cells treated with 3 mM glucose plus 1 mM taurine, the insulin levels were significantly reduced compared to controls (p<0.001; Figs. 1f, 2f, 3). The insulin
levels for the synergistic treatment were not

significantly higher than the treatment with 3 mM
glucose alone (p>0.05).

Discussion
We demonstrate here that taurine transport into pancreatic b-cells may initiate the calcium-dependent
release of insulin and GABA, independent of extracellular glucose concentrations. Experimentally, glucose concentrations are considered low if < 2.8 mM but
appropriate for insulin release at concentrations above
11 mM, although lower concentrations have elicited
physiological responses. Glucose concentrations at 3
mM can regulate glucagon release from pancreatic acells, presumably through release of GABA from b-cells
[1]. Since insulin and GABA may be co-released, we
chose to use 3 mM glucose for our studies. In both cell
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Figure 3 Comparison of insulin levels in Hit and Rin cells. Relative fluorescence intensity, a marker for amounts of protein present in the cell,
from cells represented in Figures 1 and 2 For statistical analyses, all p values are related to control cultures treated with 1 mM glucose only. A:
Relative fluorescence intensity for insulin in the b-cell line Hit-T15. B: Relative fluorescence intensity for insulin in the b-cell line Rin-m. Using 1
mM glucose in the absence of taurine (1G0T) as a control, all treatments resulted in significantly reduced insulin immunoreactivity. Legend: 0G0T
(no glucose or taurine), 3G0T (3 mM glucose, no taurine), 0G1T (no glucose, 1 mM taurine), 1G1T (1 mM each glucose plus taurine), 3G1T (3 mM
glucose, 1 mM taurine).

lines used, this glucose concentration was sufficient to
bring about a reduction in intracellular insulin levels
compared to concentrations less that 2.8 mM.
Insulin exocytosis begins with the uptake of glucose by
the b-cells [2,3] and subsequent breakdown via glycolysis. Subsequent generation of ATP closes ATP-dependent K+ channels [11]. Glucose deprivation appears to

increase KATP channel activity through cAMP-activated
protein kinase-dependent recruitment of these channel
proteins [12]. We demonstrated here that glucose deprivation suppresses insulin release, presumably by cAMPactivated protein kinase-dependent increase in K ATP
channel expression at the cell surface [12]. In the paper
by Lim et al., the use of 3 mM glucose did not
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significantly alter KATP-dependent currents; however, in
that study the islets were pre-treated with glucose for
2 hr at room temperature. It may be that in our study,
the environmental parameters may also contribute to
the observed changes in insulin levels. In our study,
treatment was for 24 h and at 37 o C and may more
appropriately describe differences seen between our data
at 0 mM, 1 mM and 3 mM.
With the significant reduction in insulin using 3 mM
glucose compared to 1 mM, we used these two conditions as physiologically relevant. When these cell lines
were treated with 1 mM taurine in the absence of glucose, taurine alone was capable of significantly reducing
the cytoplasmic insulin levels (Figs 1-3). These data may
explain our previous observations that chronic taurine
exposure may result in a chronic hypoglycemia. We

have found that mice chronically fed taurine in their
drinking water are hypoglycemic compared to agematched controls (data not shown). We further found
that when taurine-fed mice are challenged with glucose
following a 12 hour fast, there is a delay of 30 min in
peak plasma glucose levels, suggesting that these animals are better prepared to handle a sudden rise in glucose. If taurine transport into b-cells increases insulin
release, one would expect to find that chronic release of
insulin might facilitate glucose uptake, resulting in a
chronic depression in plasma glucose concentration.
Additionally, taurine is a known agonist of the
GABA A receptor [13-20]. In pancreatic islets, the
GABAA receptor is expressed on a-cells where glucagon
is synthesized and released. Taurine binding to the
GABA A receptor results in a hyperpolarization of

Figure 4 Proposed scheme by which taurine may affect insulin and GABA release from pancreatic b-cells. In this scheme, 1: taurine is
taken up into the b-cells via the taurine transporter (TauT). Once in the cytoplasm, 2: taurine inactivates the ATP-sensitive K+-channels either
directly via interaction with the sulfonylurea receptor on the channel, or indirectly via an associated protein that binds to the SUR. The
inactivation of ATP-sensitive K+-channels leads to 3: an increase in intracellular Ca++ either via voltage-sensitive calcium channels or
mitochondrial buffering. Once there is a critical Ca++ concentration, 4: exocytosis of the large dense-core vesicles containing insulin and GABA
occurs. In the in vivo pancreas, GABA would bind to GABAA receptors on a-cells and inactivate glucagon release.
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a-cells, thus inhibiting glucagon release. For our in vivo
observations, the hypoglycemia observed in chronic
taurine administration may be attributed to activation of
insulin release via transport into the b-cells, inhibition
of glucagon release via interaction of taurine with the
GABA A receptors on the a-cells, or a combination of
these events.

Conclusions
The transport of taurine into pancreatic b-cells may be
sufficient to cause the release of insulin. We believe that
the mechanism by which this can occur in b-cells
involves the interaction of taurine with the ATP-sensitive K-channels. In these cells in vivo, a rise in intracellular glucose levels results in a concomitant increase in
cytoplasmic ATP, NADH and NADPH, all required for
insulin exocytosis [21]. In part, the mechanism of this
action requires an increase in the ATP:ADP ratio, which
closes ATP-dependent K + channels [21]. Closure of
these K+-channels depolarizes the b-cells and activates
voltage-gated calcium channels. The resulting increase
in cytosolic calcium is responsible in part for the exocytosis of the insulin-containing large dense-core vesicles
(LDVC) [21]. The resulting exocytosis of the LDVC also
releases GABA, which is found in both the LDVC and
synapse-like microvesicles (SLMV) [22]. Therefore,
release of insulin and GABA from the pancreatic b-cells
requires regulation of both K+ and Ca2+ currents.
Taurine has been shown to inhibit the KATP-channels
in skeletal muscle fibers [23]. In these fibers, taurine
binds either to the sulfonylurea receptor (SUR) portion
of channel, or to some associated protein that in turn
binds to the SUR [23]. We propose the following
mechanism by which taurine might independently affect
insulin release from the pancreatic b-cells: First, taurine
is taken up by the taurine transporter (TauT) on the bcells (Fig 4, step 1). Once in the cytoplasm, taurine
binds to the SUR portion of the channel (or associated
protein which in turn binds to the SUR) and inactivates
the ATP-sensitive K+-channel (Fig 4, step 2). The inhibition of the ATP-sensitive K+-channel leads to the opening of voltage-gated calcium channels (Fig 4, step 3) or
alternately the efflux of calcium from intracellular
stores. In neurons, taurine-modulated calcium flux has
been reported [24]. Ultimately, the increase in cytoplasmic calcium concentration results in the exocytotic
release of the LDCV containing insulin and GABA.
If taurine is administered chronically, the metabolic
relevance could manifest as chronic hypoglycemia. The
significance of this in the treatment of type II diabetes
could mean that in certain cases, higher plasma insulin
levels could alleviate increases in plasma glucose
concentrations.
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